News | Stents Drug Eluting | October 11, 2019

Supraflex Drug-Eluting Stent Superior to Xience in Two-Year Target Vessel Failure

Findings of TALENT trial two-year results reinforce SMT’s Supraflex stent clinically at par with Abbott’s Xience family

Supraflex Drug-Eluting Stent Superior to Xience in Two-Year Target Vessel Failure

October 11, 2019 — The ultra-thin Supraflex drug-eluting stent (DES) from SMT maintained numerically lower outcomes at two years of follow-up in a randomized trial against Abbott’s Xience stent, according to results presented at Transcatheter Cardiovascular Therapeutics (TCT) 2019, Sept. 25-29 in San Francisco. 

Patients who got the Supraflex stent in the TALENT trial had 6.9 percent target lesion failure occur at 720 days (versus 7.9% percent of Xience recipients), according to a presentation by Azfar Zaman, M.D., cardiac catheter laboratories, Royal Freeman Hospital, Newcastle, United Kingdom.

Patrick Serruys, M.D., was the chair for the TALENT trial. The study was conducted in seven countries — the U.K., Netherlands, Poland, Spain, Italy, Hungary and Bulgaria — across 23 centers with a sample size of 1,435 patients. Xience is regarded as the global standard in safety and efficacy for drug-eluting stents. 

Presenting the findings of the TALENT trial, Zaman said, “Safety and efficacy of Supraflex SES with ultra-thin struts and biodegradable polymer were compared with Xience EES in [an] all comers-population. Supraflex was found to be non-inferior to the Xience for DOCE (device-oriented end points) at 24 months in an all comer-population.” 

Upendra Kaul, M.D., one of the leading cardiologists from India, was the co-chair of the TALENT Study. Commenting on the study, Kaul said, "There remained a perception that stents produced outside of India were superior to homegrown devices. 

There were demands from Indian manufacturers to prove that their devices are comparable to those made elsewhere in robust clinical trials.” 

The individual components of the primary endpoint suggest the difference was mainly driven by myocardial infarction (MI):

  • Target vessel MI: 3 percent versus 3.8 percent (P=0.382);
  • Cardiac death: 1.3 percent versus 1.6 percent (P=0.659); and
  • Clinically driven target lesion revascularization: 4.9 percent versus 5.3 percent (P=0.718).

Over the entire two-year study period, stent thrombosis rates were similar between Supraflex and Xience groups. However, late and very late instances were more likely with Xience (0.5 percent versus 1 percent).

Prof. R. de Winter, M.D., Academisch Medisch Centrum, Amsterdam, The Netherlands; and Zaman were the principal investigators for the TALENT trial.  

Supraflex is available in 75 countries across the world and has advanced features like a biodegradable polymer and ultrathin strut (60μm) thickness compared tothe  81 μm strut thickness and biostable polymer coating of Xience. The TALENT clinical study result matches with the published meta-analysis, highlighting the benefits of lower strut thickness. 

For more information: www.smtpl.com

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init